Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.84 |
| ▸ | F2 | P00734 | 5/20 | 0.84 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28365263 | 0.99 | F10 (0.82) | F10F2SLC29A1 | |
| SCHEMBL17507083 | 0.99 | F10 (0.82) | F10F2SLC29A1 | |
| SCHEMBL28369185 | 0.97 | F10 (0.79) | F10F2SLC29A1 | |
| SCHEMBL18365276 | 0.93 | F10 (0.85) | F10F2SLC29A1 | |
| SCHEMBL23777828 | 0.91 | F10 (0.82) | F10F2SLC29A1 | |
| SCHEMBL15883174 | 0.91 | F10 (0.82) | F10F2SLC29A1 | |
| Apixaban SCHEMBL118023 | 0.91 | F10 (1.00) | F10F2SLC29A1 | |
| Apixaban SCHEMBL15534161 | 0.90 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL14672486 | 0.90 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL5445904 | 0.90 | F10 (0.98) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082617-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | SLAYBACK PHARMA LLC (US) | 2025-03-13 | — | — | US | claimed |
| US-12194028-B2 | Stable pharmaceutical compositions of apixaban | SLAYBACK PHARMA LLC (US) | 2025-01-14 | — | — | US | claimed |
| CN-117659011-A | New method for synthesizing apixaban | 华东理工大学 | 2024-03-08 | — | — | CN | claimed |
| US-20230285368-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | SLAYBACK PHARMA LLC (US) | 2023-09-14 | — | — | US | claimed |
| CN-115385910-B | Preparation method of apixaban intermediate | 山东信谊制药有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115385910-A | Preparation method of apixaban intermediate | 山东信谊制药有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-3212620-B1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LTD FORMERLY JUBILANT LIFE SCIENCES DIVISION (IN) | 2020-11-25 | — | — | EP | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| US-9603846-B2 | Process for the preparation of apixaban | CADILA HEALTHCARE LIMITED (IN) | 2017-03-28 | — | — | US | claimed |
| WO-2016079549-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF APIXABAN | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2016-05-26 | — | — | WO | claimed |
| US-20160143894-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | CADILA HEALTHCARE LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| WO-2016020711-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2016-02-11 | — | — | WO | claimed |
| US-12521383-B2 | Stable pharmaceutical compositions of apixaban | SLAYBACK PHARMA LLC (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250319077-A1 | APIXABAN COMPOSITIONS | Novick BioSciences Private Limited (IN) | 2025-10-16 | — | — | US | disclosed |
| US-20250268881-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | SLAYBACK PHARMA LLC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250221978-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | SLAYBACK PHARMA LLC (US) | 2025-07-10 | — | — | US | disclosed |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | ZHOU JIACHENG | 2005-11-03 | — | — | US | disclosed |
| US-6919451-B2 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194028-B2 | Stable pharmaceutical compositions of apixaban | VKORC1, CYP2C9, VKORC1L1 | F10 16/4885F2 12/4885SLC29A1 1261/4885 |
| US-20160143894-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | CYP4X1, CYP4B1, NPPA | F10 123/4885F2 71/4885SLC29A1 2113/4885 |
| US-20250319077-A1 | APIXABAN COMPOSITIONS | TBXA2R, PCSK9, VKORC1 | F10 12/4885F2 18/4885SLC29A1 1978/4885 |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | TFPI, TFPI2, F2 | F10 19/4885F2 3/4885SLC29A1 4423/4885 |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | F2, TFPI, TFPI2 | F10 26/4885F2 1/4885SLC29A1 4125/4885 |
| US-20230285368-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | VKORC1, CYP2C9, VKORC1L1 | F10 16/4885F2 12/4885SLC29A1 1261/4885 |
| US-20250221978-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | PCSK9, VKORC1, CYP2C9 | F10 13/4885F2 116/4885SLC29A1 787/4885 |
| US-20250268881-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | PCSK9, VKORC1, CYP2C9 | F10 13/4885F2 116/4885SLC29A1 787/4885 |
| US-20250082617-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | VKORC1, CYP2C9, VKORC1L1 | F10 16/4885F2 12/4885SLC29A1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.